Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Patients presenting with clinical characteristics that are strongly suggestive of neuromyelitis optica spectrum disorders (NMOSD) have a high risk of developing definite NMOSD in the future. Little is known about the clinical course, treatment, and prognosis of these patients with likely NMOSD at disease onset. Methods This study prospectively recruited and visited 24 patients with the limited form of NMOSD (LF-NMOSD) at disease onset from November 2012 to June 2021. Their demographics, clinical course, longitudinal aquaporin-4 immunoglobulin G (AQP4-IgG) serology, MRI, therapeutic management, and outcome data were collected and analyzed. Results The onset age of the cohort was 38.1±12.0 years (mean±standard deviation). The median disease duration was 73.5 months (interquartile range=44.3–117.0 months), and the follow-up period was 54.2±23.8 months. At the end of the last visit, the final diagnosis was categorized into AQP4-IgG-seronegative NMOSD (n=16, 66.7%), AQP4-IgG-seropositive NMOSD (n=7, 29.2%), or multiple sclerosis (n=1, 4.2%). Seven of the 24 patients (29.2%) experienced conversion to AQP4-IgG seropositivity, and the interval from onset to this serological conversion was 37.9±21.9 months. Isolated/mixed area postrema syndrome (APS) was the predominant onset phenotype (37.5%). The patients with isolated/mixed APS onset showed a predilection for conversion to AQP4-IgG seropositivity. All patients experienced a multiphasic disease course, with immunosuppressive therapy reducing the incidence rates of clinical relapse and residual functional disability. Conclusions Definite NMOSD may be preceded by LF-NMOSD, particularly isolated/ mixed APS. Intensive long-term follow-up and attack-prevention immunotherapeutic management is recommended in patients with LF-NMOSD.
Abstract
Background and Purpose Patients presenting with clinical characteristics that are strongly suggestive of neuromyelitis optica spectrum disorders (NMOSD) have a high risk of developing definite NMOSD in the future. Little is known about the clinical course, treatment, and prognosis of these patients with likely NMOSD at disease onset. Methods This study prospectively recruited and visited 24 patients with the limited form of NMOSD (LF-NMOSD) at disease onset from November 2012 to June 2021. Their demographics, clinical course, longitudinal aquaporin-4 immunoglobulin G (AQP4-IgG) serology, MRI, therapeutic management, and outcome data were collected and analyzed. Results The onset age of the cohort was 38.1±12.0 years (mean±standard deviation). The median disease duration was 73.5 months (interquartile range=44.3–117.0 months), and the follow-up period was 54.2±23.8 months. At the end of the last visit, the final diagnosis was categorized into AQP4-IgG-seronegative NMOSD (n=16, 66.7%), AQP4-IgG-seropositive NMOSD (n=7, 29.2%), or multiple sclerosis (n=1, 4.2%). Seven of the 24 patients (29.2%) experienced conversion to AQP4-IgG seropositivity, and the interval from onset to this serological conversion was 37.9±21.9 months. Isolated/mixed area postrema syndrome (APS) was the predominant onset phenotype (37.5%). The patients with isolated/mixed APS onset showed a predilection for conversion to AQP4-IgG seropositivity. All patients experienced a multiphasic disease course, with immunosuppressive therapy reducing the incidence rates of clinical relapse and residual functional disability. Conclusions Definite NMOSD may be preceded by LF-NMOSD, particularly isolated/ mixed APS. Intensive long-term follow-up and attack-prevention immunotherapeutic management is recommended in patients with LF-NMOSD.
참고문헌 (30)
- Wingerchuk DM, "The clinical course of neuromyelitis optica(Devic’s syndrome)", Neurology, 53, pp.1107~1114 (1999)
- Lennon VA, "A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis", Lancet, 364, pp.2106~2112 (2004)
- Wingerchuk DM, "The spectrum of neuromyelitis optica", Lancet Neurol, 6, pp.805~815 (2007)
- Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
- Kleiter I, "Neuromyelitis optica : evaluation of 871 attacks and 1, 153 treatment courses", Ann Neurol, 79, pp.206~216 (2016)
- Shosha E, "Area postrema syndrome : frequency, criteria, and severity in AQP4-IgG-positive NMOSD", Neurology, 91, pp.e1642~e1651 (2018)
- Waters PJ, "Evaluation of aquaporin-4 antibody assays", Clin Exp Neuroimmunol, 5, pp.290~303 (2014)
- Zhou Y, "Myelin oligodendrocyte glycoprotein antibody-associated demyelination : comparison between onset phenotypes", Eur J Neurol, 26, pp.175~183 (2019)
- Gold SM, "Sex differences in autoimmune disorders of the central nervous system", Semin Immunopathol, 41, pp.177~188 (2019)
- Thompson AJ, "Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria", Lancet Neurol, 17, pp.162~173 (2018)
- Jarius S, "Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis", J Neurol Sci, 298, pp.158~162 (2010)
- Jarius S, "Antibody to aquaporin-4 in the long-term course of neuromyelitis optica", Brain, 131, pp.3072~3080 (2008)
- Kim W, "Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4", Mult Scler, 18, pp.578~586 (2012)
- Stellmann JP, "Immunotherapies in neuromyelitis optica spectrum disorder : efficacy and predictors of response", J Neurol Neurosurg Psychiatry, 88, pp.639~647 (2017)
- Matiello M, "NMO-IgG predicts the outcome of recurrent optic neuritis", Neurology, 70, pp.2197~2200 (2008)
- Weinshenker BG, "Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis", Ann Neurol, 59, pp.566~569 (2006)
- Waters PJ, "Serologic diagnosis of NMO : a multicenter comparison of aquaporin-4-IgG assays", Neurology, 78, pp.665~671 (2012)
- Pittock SJ, "Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression", Arch Neurol, 63, pp.964~968 (2006)
- Dubey D, "Association of extension of cervical cord lesion and area postrema syndrome with neuromyelitis optica spectrum disorder", JAMA Neurol, 74, pp.359~361 (2017)
- Hyun JW, "Value of area postrema syndrome in differentiating adults with AQP4 vs. MOG antibodies", Front Neurol, 11, pp.396~ (2020)
- Zhou C, "Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: a retrospective study", Rev Neurol(Paris), 177, pp.400~406 (2021)
- Roemer SF, "Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis", Brain, 130, pp.1194~1205 (2007)
- Juryńczyk M, "Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO", MS overlap syndromes, 2016, pp.263, 140~149
- Hor JY, "Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide", Front Neurol, 11, pp.501~ (2020)
- Flanagan EP, "Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders", JAMA Neurol, 72, pp.81~87 (2015)
- Fang W, "Short segment myelitis as the initial and only manifestation of aquaporin-4immunoglobulin G-positive neuromyelitis optica spectrum disorders", Ther Adv Neurol Disord, 13, pp.1756286419898594~ (2020)
- Sellner J, "EFNS guidelines on diagnosis and management of neuromyelitis optica", Eur J Neurol, 17, pp.1019~1032 (2010)
- Sahraian MA, "Diagnosis and management of neuromyelitis optica spectrum disorder(NMOSD)in Iran : a consensus guideline and recommendations", Mult Scler Relat Disord, 18, pp.144~151 (2017)
- Trebst C, "Update on the diagnosis and treatment of neuromyelitis optica : recommendations of the Neuromyelitis Optica Study Group(NEMOS)", J Neurol, 261, pp.1~16 (2014)
- Kleiter I, "Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions", Neurol Neuroimmunol Neuroinflamm, 5, pp.e504~ (2018)